Gyre Therapeutics Updates Corporate Presentation
Gyre Therapeutics, Inc. (GYRE) announced on June 1, 2026, that it made available an updated corporate presentation. The presentation details the company's pipeline, which includes marketed products like ETUARY™ (pirfenidone) and drug candidates such as F351 (hydronidone) for liver fibrosis, with an NDA accepted by China's NMPA. It also highlights advancements in targeted protein degraders for cancer and inflammatory diseases, including a CDK2-Cyclin E degrader with an anticipated IND in Q1 2027, and a TYK2-JAK1 degrader. Furthermore, Gyre is advancing Degrader-Antibody Conjugates (DACs) as a next-generation therapeutic platform and emphasizes the strategic advantages of its China-based operations for drug discovery and development.
Key Highlights
- Gyre Therapeutics made available an updated corporate presentation on June 1, 2026.
- The presentation covers pipeline assets including ETUARY™ (pirfenidone), F351 (hydronidone), CG923308, F528, CG620953, CG001419, and CG009301.
- The company highlights its China operations for discovery, validation, and development of therapeutics.
- F351 (hydronidone) has an NDA accepted by China NMPA in May 2026 for CHB-associated liver fibrosis.
- A CDK2-Cyclin E dual degrader for solid tumors has an IND anticipated in Q1 2027.
- A TYK2-JAK1 dual degrader for inflammatory diseases (CG620953) shows efficacy in preclinical models.
- The company is developing Degrader-Antibody Conjugates (DACs) as next-generation ADCs.
Price Impact
More from GYRE